Swipe om te navigeren naar een ander artikel
Anxiety and depression disorders are associated with significantly lower health-related quality of life (HRQL). The EQ-5D is a commonly used generic measure of HRQL; it captures mental health through a single domain—the anxiety/depression dimension. Evidence on the responsiveness of this measure in assessing changes in mental health changes is limited.
To examine the performance of the anxiety/depression dimension (A/D) of the 3- and 5-level (3L and 5L) versions of the EQ-5D in assessing changes in mental health.
Data from two patient populations were used: 495 adults post-discharge from general internal medicine ward (EQ-5D-3L), and 225 type 2 diabetes patients who screened positive for depressive symptoms (EQ-5D-5L). Anchor-based approach along with effect sizes (ES) and ROC analysis was used. Anchors included patient health questionnaire 9-items “PHQ9” and generalized anxiety disorder 2-item questionnaire “GAD2” for EQ-5D-3L, and PHQ9 and SF-12 mental composite summary scores (MCS) for EQ-5D-5L. A/D change was quantified as the difference between follow-up and baseline levels.
The A/D dimension of the EQ-5D-3L showed limited responsiveness to changes in depressive symptoms measured by PHQ9 and for anxiety symptoms measured by GAD2, whereby in those who improved or deteriorated in either symptom, more than half of the patients did not have an A/D change. In the ROC analysis, the A/D dimension of the EQ-5D-3L showed weak performance with C-indices ranging from 0.58 to 0.63 and probability of detection of depressive or anxiety symptoms ranging between 20 and 40%, which are all well below acceptable ranges. Similar results were observed for the A/D dimension of the EQ-5D-5L; although the performance was slightly better, it was still below acceptable range. In patients who improved or deteriorated based on the PHQ9 or MCS, around a third had no changes on the A/D dimension. The performance of the A/D dimension of the EQ-5D-5L was also very limited with C-indices ranging between 0.67 and 0.76, and probability of detection between 50 and 67%, slightly better than that of the 3L, yet unsatisfactory.
Although the A/D of both EQ-5D-3L and 5L was limited in capturing changes in mental health in these populations, the 5L was slightly more responsive than the 3L. While the performance was better for depressive than anxiety symptoms, it varied by the direction of change. Further research using other measures of mental health in other populations is warranted.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
EuroQol Group. (1990). EuroQol: A new facility for the measurement of health-related quality of life. Health Policy, 16(3), 199–208. CrossRef
Agborsangaya, C. B., Lahtinen, M., Cooke, T., & Johnson, J. A. (2014). Comparing the EQ-5D 3L and 5L: Measurement properties and association with chronic conditions and multimorbidity in the general population. Health & Quality of Life Outcomes, 12, 74. CrossRef
Pattanaphesaj, J., & Thavorncharoensap, M. (2015). Measurement properties of the EQ-5D-5L compared to EQ-5D-3L in the Thai diabetes patients. Health & Quality of Life Outcomes, 13, 14. CrossRef
Pyne, J. M., Patterson, T. L., Kaplan, R. M., & Ho, S. (1997). Preliminary longitudinal assessment of quality of life in patients with major depression. Psychopharmacology Bulletin, 33(1), 23. PubMed
Sapin, C., Fantino, B., Nowicki, M.-L., & Kind, P. (2004). Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health and Quality of Life Outcomes, 2(1), 1. CrossRef
Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., et al. (1998). The Mini-International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry, 59, 22 PubMed
Public Health Agency of Canada. (2016). Evaluation of programs for the treatment of schizophrenia: A health economic perspective. http://www.publichealth.gc.ca. Accessed Dec 2016.
Revicki, D. A., Cella, D., Hays, R. D., Sloan, J. A., Lenderking, W. R., & Aaronson, N. K. (2006). Responsiveness and minimal important differences for patient reported outcomes. Health and Quality of Life Outcomes, 4(1), 1–5. CrossRef
Johnson, J. A., Al Sayah, F., Wozniak, L., Rees, S., Soprovich, A., Qiu, W., et al. (2014). Collaborative care versus screening and follow-up for patients with diabetes and depressive symptoms: Results of a primary care-based comparative effectiveness trial. Diabetes Care, 37(12), 3220–3226. CrossRefPubMed
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003). Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Medical Care, 41(5), 582–592. PubMed
Ware, J. E. K. M., & Keller, S. D. (1995). SF-12: How to score the SF-12 physical and mental health summary scales. Boston: The Health Institute, New England Medical Center.
Rosenthal, J. A. (1996). Qualitative descriptors of strength of association and effect size. Journal of Social Service Research, 21(4), 37–59. CrossRef
Pyne, J. M., Patterson, T. L., Kaplan, R. M., Gillin, J. C., Koch, W. L., & Grant, I. (1997). Assessment of the quality of life of patients with major depression. Psychiatric Services, 33, 23
Gerhards, S. A. H., Huibers, M. J. H., Theunissen, K. A. T. M., de Graaf, L. E., Widdershoven, G. A. M., & Evers, S. M. A. A. (2011). The responsiveness of quality of life utilities to change in depression: A comparison of instruments (SF-6D, EQ-5D, and DFD). Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 14(5), 732–739. CrossRef
Mulhern, B., Mukuria, C., Barkham, M., Knapp, M., Byford, S., Soeteman, D., et al. (2014). Using generic preference-based measures in mental health: Psychometric validity of the EQ-5D and SF-6D. The British Journal of Psychiatry: The Journal of Mental Science, 205(3), 236–243. CrossRef
Bhadhuri, A., Jowett, S., Jolly, K., & Al-Janabi, H. (2017). A comparison of the validity and responsiveness of the EQ-5D-5L and SF-6D for measuring health spillovers: A study of the family impact of meningitis. Medical Decision Making: An International Journal of the Society for Medical Decision Making, 37(8), 882–893. CrossRef
Cheung, P. W. H., Wong, C. K. H., Lau, S. T., & Cheung, J. P. Y. (2017). Responsiveness of the EuroQoL 5-dimension (EQ-5D) in adolescent idiopathic scoliosis. European Spine Journal: Official Publication of the European Spine Society, The European Spinal Deformity Society, and The European Section of the Cervical Spine Research Society, 27, 278 CrossRef
Wijnen, B. F. M., Mosweu, I., Majoie, M. H. J. M., Ridsdale, L., de Kinderen, R. J. A., Evers, S. M. A. A., et al. (2017). A comparison of the responsiveness of EQ-5D-5L and the QOLIE-31P and mapping of QOLIE-31P to EQ-5D-5L in epilepsy. The European Journal of Health Economics. https://doi.org/10.1007/s10198-017-0928-0 PubMedCrossRefPubMedCentral
Johnson, J. A., Lier, D. A., Soprovich, A., Al Sayah, F., Qiu, W., & Majumdar, S. R. (2016). Cost-effectiveness evaluation of collaborative care for diabetes and depression in primary care. American Journal of Preventive Medicine, 51(1), e13–e20. CrossRef
Al Sayah, F JJ, & Ohinmaa, A. (Eds.). (2016). The performance of EQ-5D-5L and VR-12 in assessing mental health. ISOQOL 23rd annual conference (pp. 19–22). Copenhagen: Quality of Life Research.
- Responsiveness of the anxiety/depression dimension of the 3- and 5-level versions of the EQ-5D in assessing mental health
Fatima Al Sayah
Jeffrey A. Johnson
- Springer International Publishing